Examining the link between quadriceps strength and frailty in cirrhosis patients
Is There an Association Between Quadriceps Strength and Different Markers of Fragility in Patients With Cirrhosis?
NA · University Hospital, Clermont-Ferrand · NCT06133127
This study is testing if stronger leg muscles can help doctors understand how frail patients with cirrhosis are.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 45 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | University Hospital, Clermont-Ferrand (other) |
| Locations | 1 site (Clermont-Ferrand) |
| Trial ID | NCT06133127 on ClinicalTrials.gov |
What this trial studies
This study investigates the relationship between quadriceps strength and various markers of frailty in patients diagnosed with cirrhosis. It aims to validate the Liver Frailty Index (LFI) by comparing it to isometric maximal lower limb strength measurements. Participants will undergo frailty assessments to determine how muscle strength correlates with their frailty status. The study is conducted at the University Hospital Estaing in Clermont-Ferrand, focusing on patients under the care of a physician at this institution.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with a diagnosis of liver cirrhosis who are receiving care at the University Hospital Estaing.
Not a fit: Patients with conditions such as hepatocellular carcinoma, severe cognitive dysfunction, or those unable to participate in physical activity may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the assessment and management of frailty in cirrhosis patients, potentially leading to better health outcomes.
How similar studies have performed: While the specific association being studied is novel, previous research has indicated the importance of muscle strength in frailty assessments, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: SUBJECT : * with a diagnosis of liver cirrhosis (regardless of cirrhosis stage and etiology) * under the care of a physician practising in the University Hospital Estaing in Clermont-Ferrand * affiliated to the french social security system Exclusion Criteria: SUBJECT: * with hepatocellular carcinoma * with HIV infection * with hepatic encephalopathy grade ≥ 2 * with cognitive dysfunction * with contraindication for physical activity * with knee pain/knee disorders * pregnant or breastfeeding * under protective supervision (guardianship, curatorship, protection of the court)
Where this trial is running
Clermont-Ferrand
- CHU clermont-ferrand — Clermont-Ferrand, France (RECRUITING)
Study contacts
- Principal investigator: Armando ABERGEL — aabergel@chu-clermontferrand.fr
- Study coordinator: Lise LACLAUTRE
- Email: promo_interne_drci@chu-clermontferrand.fr
- Phone: 334.73.754.963
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Cirrhosis, Frailty markers, Quadriceps strength